ES2620751T3 - Nuevos compuestos útiles como inhibidores de S100 - Google Patents

Nuevos compuestos útiles como inhibidores de S100 Download PDF

Info

Publication number
ES2620751T3
ES2620751T3 ES15724640.6T ES15724640T ES2620751T3 ES 2620751 T3 ES2620751 T3 ES 2620751T3 ES 15724640 T ES15724640 T ES 15724640T ES 2620751 T3 ES2620751 T3 ES 2620751T3
Authority
ES
Spain
Prior art keywords
alkyl
optionally substituted
cycloalkyl
independently selected
attached
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15724640.6T
Other languages
English (en)
Spanish (es)
Inventor
Ulf Wellmar
David LIBERG
Maria EKBLAD
Marie BAINBRIDGE
Stephen EAST
Jonathan Hargrave
Natacha Prevost
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Active Biotech AB
Original Assignee
Active Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech AB filed Critical Active Biotech AB
Application granted granted Critical
Publication of ES2620751T3 publication Critical patent/ES2620751T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
ES15724640.6T 2014-05-23 2015-05-22 Nuevos compuestos útiles como inhibidores de S100 Active ES2620751T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14169757 2014-05-23
EP14169757 2014-05-23
PCT/EP2015/061468 WO2015177367A1 (en) 2014-05-23 2015-05-22 Novel compounds useful as s100-inhibitors

Publications (1)

Publication Number Publication Date
ES2620751T3 true ES2620751T3 (es) 2017-06-29

Family

ID=50774707

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15724640.6T Active ES2620751T3 (es) 2014-05-23 2015-05-22 Nuevos compuestos útiles como inhibidores de S100

Country Status (12)

Country Link
US (1) US9771372B2 (2)
EP (1) EP2991990B1 (2)
JP (1) JP6580074B2 (2)
KR (1) KR20170005868A (2)
CN (1) CN106414448B (2)
AU (1) AU2015261775B2 (2)
BR (1) BR112016024749A2 (2)
CA (1) CA2948436A1 (2)
EA (1) EA030604B1 (2)
ES (1) ES2620751T3 (2)
MX (1) MX2016014483A (2)
WO (1) WO2015177367A1 (2)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7392951B2 (ja) 2018-04-27 2023-12-06 国立大学法人 岡山大学 抗ｓ１００ａ８／ａ９抗体とその用途
US11197908B2 (en) 2018-07-17 2021-12-14 The Board Of Trustees Of The University Of Arkansas Peptoids and methods for attenuating inflammatory response
EP4052725A4 (en) 2019-10-30 2024-07-17 National University Corporation Okayama University PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR INFLAMMATORY LUNG DISEASE
WO2023209141A1 (en) 2022-04-29 2023-11-02 Westfälische Wilhelms-Universität Münster Benzo[d]imidazo[1,2-a]imidazoles and their use in diagnosis
WO2025132458A1 (en) 2023-12-18 2025-06-26 Chiesi Farmaceutici S.P.A. Pyridazinyl amino derivatives as alk5 inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
EP1305308B1 (en) 2000-07-26 2006-12-20 Smithkline Beecham Plc Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
CN1235583C (zh) * 2001-03-05 2006-01-11 特兰斯泰克制药公司 用作治疗剂的苯并咪唑衍生物
GB0117506D0 (en) 2001-07-18 2001-09-12 Bayer Ag Imidazopyridinones
SE0104331D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Novel compounds
DK1482931T3 (da) * 2002-03-05 2011-12-19 Transtech Pharma Inc Mono- og bicycliske azolderivater der inhiberer interaktionen af ligander med RAGE
US20060111416A1 (en) 2004-11-24 2006-05-25 Lane Charlotte A L Octahydropyrrolo[3,4-C]pyrrole derivatives
WO2008042282A2 (en) 2006-09-28 2008-04-10 Exelixis, Inc. Imidazole-4, 5-dicarboxamide derivatives as jak-2 modulators
EP2132207A2 (en) 2007-03-23 2009-12-16 Amgen Inc. Heterocyclic compounds and their uses
EP1986009A1 (en) * 2007-04-26 2008-10-29 Active Biotech AB Screening method
WO2008157270A1 (en) 2007-06-13 2008-12-24 Smithkline Beecham Corporation Farnesoid x receptor agonists
PE20091439A1 (es) * 2008-01-22 2009-10-19 Takeda Pharmaceutical Compuestos triciclicos como antagonistas de crf
TW201004941A (en) 2008-07-16 2010-02-01 Wyeth Corp Alpha7 nicotinic acetylcholine receptor inhibitors
AU2010221417A1 (en) 2009-03-02 2011-09-22 Sirtris Pharmaceuticals, Inc. 8-substituted quinolines and related analogs as sirtuin modulators
MX2014005285A (es) 2011-11-03 2014-05-30 Hoffmann La Roche Compuestos biciclicos de piperazina.
GB201321728D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents

Also Published As

Publication number Publication date
KR20170005868A (ko) 2017-01-16
WO2015177367A1 (en) 2015-11-26
AU2015261775B2 (en) 2019-07-11
EA201692405A1 (ru) 2017-06-30
EP2991990A1 (en) 2016-03-09
US20170204098A1 (en) 2017-07-20
EA030604B1 (ru) 2018-08-31
JP6580074B2 (ja) 2019-09-25
CA2948436A1 (en) 2015-11-26
US9771372B2 (en) 2017-09-26
EP2991990B1 (en) 2017-02-01
HK1221463A1 (en) 2017-06-02
CN106414448A (zh) 2017-02-15
BR112016024749A2 (pt) 2017-08-15
AU2015261775A1 (en) 2016-12-08
MX2016014483A (es) 2017-01-23
CN106414448B (zh) 2019-04-19
JP2017516772A (ja) 2017-06-22

Similar Documents

Publication Publication Date Title
SV2016005328A (es) Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1
AR108388A2 (es) Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas
ES2620751T3 (es) Nuevos compuestos útiles como inhibidores de S100
PE20221339A1 (es) Inhibidores de parp1
AR098147A1 (es) Composiciones herbicidas que contienen amidas de ácido n-(1,3,4-oxadiazol-2-il)arilcarboxílico
AR115949A1 (es) Compuestos heterocíclicos
AR112273A1 (es) Amidas heterocíclicas de 5 miembros y bicíclicas como inhibidores de rock
AR092293A1 (es) Amidas de acido n-(1,2,5-oxadiazol-3-il)-, n-(1,3,4-oxadiazol-2-il)-, n-(tetrazol-5-il)- y n-(triazol-5-il)-arilcarboxilico y su uso como herbicidas
AR101367A1 (es) Pirimidinonas como inhibidores del factor xia
ES2669189T3 (es) Compuestos de carbazol útiles como inhibidores del bromodominio
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
AR075510A1 (es) Inhibidores del virus de la hepatitis c
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa
AR087919A1 (es) Heterociclos biciclicos como inhibidores de irak4
AR092270A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR100807A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
PE20170303A1 (es) Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas
AR090091A1 (es) Sulfin- y sulfonimidoilbenzamidas de accion herbicida
AR095351A1 (es) Inhibidores de histona desacetilasa (hdac)
CY1124479T1 (el) Ενωσεις που περιεχουν υποκατεστημενο αζωτο
CU20210023A7 (es) Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4
AR101198A1 (es) Pirimidinas 2,5-sustituidas como inhibidores de pde4b
MX374383B (es) Derivados de carboxamida como inhibidores de smurf-1
AR101197A1 (es) Pirimidinas 2,5-sustituidas
MX2016017405A (es) Compuestos derivados de 2-(3-piridinil)-1h-benzimidazol y medicamentos que los contienen.